Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
IN3BIO
Glasgow, Scotland, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
IN3BIO's lead cancer vaccine program (IN01) is in Phase I/II clinical trials for colorectal cancer, targeting mutant KRAS, NRAS, or BRAF tumors. Previous studies in NSCLC with their platform showed a median progression-free survival of 17.5 months versus 11 months for EGFR tyrosine kinase inhibitor alone, indicating improved outcomes. Other preclinical programs target additional growth factors implicated in cancer progression.
- Therapeutic areas
- Infectious DiseasesOncology
- Modalities
- VaccineRecombinant proteinBiologic
- Industry
- Biotech
02
Partnerships
3P Biopharmaceuticals
Beyond the preview
Go deeper on IN3BIO.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IN3BIO.